Telix’s new investigational prostate cancer imaging product is intended to address the unmet needs of patients, ..... and expand patient reach using Telix’s established nuclear pharmacy distribution partnerships and industry-leading on-time reliability
so, its an additional product to meet unmet needs
and
there was discussion of Illuccix 2.0, but we didn't have these details on the new product.
I don't believe it will replace existing Illuccix, but it does have some attributes, apparently, to serve the unmet market needs
Telix’s new investigational prostate cancer imaging product is...
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.20 |
Change
0.590(3.55%) |
Mkt cap ! $5.746B | |||
| Open | High | Low | Value | Volume |
| $16.65 | $17.45 | $16.63 | $17.38M | 1.015M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2558 | $17.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.21 | 5128 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$17.16 |
Change
0.590 ( 3.29 %) |
||||
| Open | High | Low | Volume | ||
| $16.90 | $17.45 | $16.77 | 213384 | ||
| Last updated 15.59pm 17/06/2024 ? | |||||
| TLX (ASX) Chart |
